<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621553</url>
  </required_header>
  <id_info>
    <org_study_id>STU 062010-055</org_study_id>
    <nct_id>NCT03621553</nct_id>
  </id_info>
  <brief_title>Vitamin D Homeostasis in Sarcoidosis</brief_title>
  <official_title>Vitamin D Homeostasis in Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the relationship between vitamin-D status and severity of sarcoidosis,
      and the effects of vitamin-D repletion in vitamin-D insufficient patients with sarcoidosis.
      Half the patients with sarcoidosis who are vitamin-D insufficient will receive standard
      vitamin-D supplementation via standard regimen while the other half will receive a placebo.
      Sarcoidosis patients who are vitamin-D sufficient will also act as controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcoidosis is a multi-system inflammatory disease characterized by T-helper lymphocyte
      hyperactivity leading to granulomatous inflammation. The granuloma cells autonomously convert
      25-hydroxy-vitamin-D (25OHD) to the active metabolite 1,25-dihydroxy-vitamin-D (1,25OH2D)
      independent of normal feedback control but dependent on substrate (25OHD) concentration.

      Circulating 1,25OH2D exerts both anti-inflammatory and mineral metabolic actions. Deficiency
      of 25OHD limits substrate-dependent 1,25OH2D synthesis, diminishes anti-antigenic innate
      immunity and augments pro-inflammatory adaptive immunity. Thus, low vitamin-D stores could
      aggravate sarcoid inflammation while repletion of vitamin-D stores could mitigate
      inflammation in sarcoidosis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2010</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Vitamin-D insufficient subjects will receive either vitamin D2 repletion or placebo Vitamin-D sufficient subjects will be observed without treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Groups separated by a) use / non-use of oral prednisone, and b) status of serum 25-hydroxy-vitamin-D level (sufficient or insufficient). Those who are vitamin-D insufficient will be randomized to receive either vitamin D2 or placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lung function from baseline</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>(Measurement at end of study)/(measurement at enrollment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in King's Sarcoidosis Questionnaire Score</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>Standard validated questionnaire for assessing the impact of sarcoidosis on quality of life. Questions address symptoms, activities and psychosocial impacts of disease. It consists of 29 questions on general health, medications, and symptoms in lung, skin, and eyes, summed to derive a total score. Each question is scored on a scale of 1 (worst) to 7 (best). Minimum total score = 5 (poorest health). Maximum total score = 203 (best health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in six minute walk distance</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>(Measurement at end of study)/(measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood cell counts from complete blood count (CBC)</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>(Measurement at study point)/(initial measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic profile from complete metabolic panel (CMP)</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>(Measurement at study point)/(initial measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum vitamin-D metabolite concentration</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>(Measurement at study point)/(initial measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum angiotensin converting enzyme (ACE) concentration</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>(Measurement at study point)/(initial measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum serum gamma-globulin concentration</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>(Measurement at study point)/(initial measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum C-reactive protein (CRP) concentration</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>(Measurement at study point)/(initial measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum tumor Necrosis factor-alpha (TNF-alpha) concentration</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>(Measurement at study point)/(initial measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum interferon-gamma (IFN-gamma) concentration</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>(Measurement at study point)/(initial measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum interleukin concentration</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>(Measurement at study point)/(initial measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24 hour urine calcium/creatinine ratio</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>(Measurement at study point)/(initial measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24 hour urine deoxypyridinoline concentration</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <description>(Measurement at study point)/(initial measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fractional lung tissue volume on computed/positron emission tomography (PET/CT)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>(Measurement at end of study)/(measurement at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fluoro-deoxyglucose (FDG) uptake on PET/CT</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>(Measurement at end of study)/(measurement at enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone density z-score</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>(Measurement at end of study)/(measurement at enrollment)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Sarcoidosis</condition>
  <condition>Vitamin D Insufficiency</condition>
  <arm_group>
    <arm_group_label>Low vit-D, Ergocalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Vitamin D2 (Ergocalciferol) 50,000 units will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.
Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low vit-D, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Placebo capsules of identical size and appearance will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.
Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal vit-D, control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Normal serum vitamin D level, split by use or non-use of systemic corticosteroid.
Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergocalciferol</intervention_name>
    <description>Vitamin D2 50,000 units</description>
    <arm_group_label>Low vit-D, Ergocalciferol</arm_group_label>
    <other_name>Vitamin D2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic ergocalciferol 50,000 units</description>
    <arm_group_label>Low vit-D, Placebo</arm_group_label>
    <other_name>Placebo oral tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Citrate with Vitamin D2</intervention_name>
    <description>To meet the recommended minimum daily dietary requirements</description>
    <arm_group_label>Low vit-D, Ergocalciferol</arm_group_label>
    <arm_group_label>Low vit-D, Placebo</arm_group_label>
    <arm_group_label>Normal vit-D, control</arm_group_label>
    <other_name>Citracal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable medical condition defined as no hospitalization or emergency room visit in the
             previous 3 months

          -  No evidence of active pulmonary or systemic infection

          -  No other active inflammatory disease,

          -  No active malignancy.

          -  Normal serum ionized calcium level

        Exclusion Criteria:

          -  Hospitalization or emergency room visit in the previous 3 months

          -  Evidence of active pulmonary or systemic infection

          -  Evidence of active other inflammatory disease

          -  Evidence of active malignancy

          -  Elevated serum ionized calcium level
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Connie Hsia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center, and Parkland Health and Hospital System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Capolongo G, Xu LH, Accardo M, Sanduzzi A, Stanziola AA, Colao A, Agostini C, Zacchia M, Capasso G, Adams-Huet B, Moe OW, Maalouf NM, Sakhaee K, Hsia CC. Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis. J Investig Med. 2016 Jun;64(5):1025-34. doi: 10.1136/jim-2016-000101. Epub 2016 Apr 6.</citation>
    <PMID>27053725</PMID>
  </results_reference>
  <results_reference>
    <citation>Vieth R. Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):575-9. Review.</citation>
    <PMID>15225842</PMID>
  </results_reference>
  <results_reference>
    <citation>Bolland MJ, Wilsher ML, Grey A, Horne AM, Fenwick S, Gamble GD, Reid IR. Randomised controlled trial of vitamin D supplementation in sarcoidosis. BMJ Open. 2013 Oct 23;3(10):e003562. doi: 10.1136/bmjopen-2013-003562.</citation>
    <PMID>24157819</PMID>
  </results_reference>
  <results_reference>
    <citation>Kamphuis LS, Bonte-Mineur F, van Laar JA, van Hagen PM, van Daele PL. Calcium and vitamin D in sarcoidosis: is supplementation safe? J Bone Miner Res. 2014 Nov;29(11):2498-503. doi: 10.1002/jbmr.2262.</citation>
    <PMID>24753153</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified participant data for primary and secondary outcome measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within 6 months of study completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external independent review panel. Requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

